In a trial, once-daily buntanetap halted cognitive decline in early-stage Parkinson's and improved cognition in patients with mild dementia.| Parkinson's News Today
Buntanetap lowered amyloid-beta and tau levels in people with early Alzheimer's disease and its developer Annovis Bio is planning more trials.| Alzheimer's News Today
The safety and efficacy of buntanetap therapy are comparable in early Alzheimer’s patients regardless of APOE4 status, per new trial data.| Alzheimer's News Today
Buntanetap, a small molecule from Annovis Bio, improved cognitive function in people with mild Alzheimer’s with certain biomarkers.| Alzheimer's News Today